While tech bros have been busy promising AI will cure cancer and solve world hunger, life sciences companies are quietly grappling with a more mundane reality: how to govern artificial intelligence without killing patients or getting sued into oblivion.
The solution isn't particularly glamorous. It involves establishing AI Centers of Excellence and multidisciplinary governance teams – basically committees that actually know what they're doing. These organizations are defining operating models with detailed processes and procedures, because apparently "move fast and break things" doesn't work when those things are human lives.
Risk assessment has become the new obsession throughout the AI lifecycle. Companies are addressing everything from AI hallucinations to potential misuse, implementing mitigation and detection strategies. It turns out that when your AI model starts making things up about drug interactions, that's not just embarrassing – it's potentially lethal.
When your AI hallucinates about pharmaceuticals, the consequences aren't just awkward—they're deadly.
The regulatory landscape is similarly thrilling. Organizations are updating standard operating procedures to incorporate AI-specific data governance while managing HIPAA and GDPR requirements. Because nothing says innovation like compliance documentation.
Behind all this bureaucracy lies a set of principles that actually make sense. High stakes demand high standards of oversight. Scientific evidence and expert consensus drive the rules, not Silicon Valley hype. The frameworks build on established ethical guidelines from organizations like the OECD and G7, promoting transparency while balancing innovation needs. Training must encompass all stakeholders including developers, end users, and leadership to ensure proper understanding of ethical AI principles.
The OECD's influence runs deep here. Their 2019 AI recommendation established five core principles that now underpin major regulations like the EU AI Act and NIST frameworks. These aren't just suggestions – they're shaping global policy.
Operationally, companies are implementing staged governance processes with cross-functional committees evaluating strategic, technical, legal, and reputational risks. They're calibrating governance levels according to risk profiles, leveraging existing regulatory bodies and compliance tools already familiar to life sciences organizations. The three-stage approach includes concept review and approval where stakeholders assess cost-benefit analysis, design and deployment with established risk management standards, and continuous monitoring to ensure AI models remain aligned with business purposes. Demographic data collection helps identify and mitigate bias through statistical analysis and counterfactual testing to reveal potential discrimination issues.
The smart money is on utilizing established review processes like Medical, Legal, and Regulatory reviews to inform AI governance. It's not revolutionary, but it works.
The reality is stark: foster ongoing governance adaptation or face the consequences. Continual learning from usage patterns, emerging regulations, and technological advances isn't optional anymore.